Opportunities Preloader

Please Wait.....

Report

Bronchopulmonary Dysplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Industry Report I 2022-04-29 I 69 Pages I Global Markets Direct

Bronchopulmonary Dysplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Drugs In Development, 2022, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection, premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 12 and 2 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchopulmonary Dysplasia - Overview
Bronchopulmonary Dysplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bronchopulmonary Dysplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
Advent Therapeutics Inc
Airway Therapeutics Inc
APIE Therapeutics Inc
Ayuvis Research Inc
Boehringer Ingelheim International GmbH
Chiesi Farmaceutici SpA
Exo Biologics SA
Insmed Inc
MediPost Co Ltd
Meridigen Biotech Co Ltd
Orphanix GmbH
Radikal Therapeutics Inc
Syntrix Pharmaceuticals
Takeda Pharmaceutical Co Ltd
The Cell Factory BVBA
Trimunocor Ltd
Velvio GmbH
Bronchopulmonary Dysplasia - Drug Profiles
APT-D - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVR-48 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologics for Autoimmune Disorders, Bronchopulmonary Dysplasia, Inflammation and Injuries - Drug Profile
Product Description
Mechanism Of Action
History of Events
CFMEV-132 - Drug Profile
Product Description
Mechanism Of Action
Drugs for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
History of Events
NVP-13 - Drug Profile
Product Description
Mechanism Of Action
NVP-19 - Drug Profile
Product Description
Mechanism Of Action
perfluorooctyl bromide - Drug Profile
Product Description
Mechanism Of Action
pioglitazone + B-YL - Drug Profile
Product Description
Mechanism Of Action
Pneumostem - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-901 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-908 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Surfactant Associated Protein D Replacement for Bronchopulmonary Dysplasia and Lung Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
SX-576 - Drug Profile
Product Description
Mechanism Of Action
History of Events
tiotropium bromide - Drug Profile
Product Description
Mechanism Of Action
UMC-11901 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
History of Events
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
History of Events
zelpultide alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Bronchopulmonary Dysplasia - Dormant Projects
Bronchopulmonary Dysplasia - Discontinued Products
Bronchopulmonary Dysplasia - Product Development Milestones
Featured News & Press Releases
Mar 31, 2022: Airway Therapeutics announces first patient dosed in phase 1b trial of AT-100 in preterm infants at risk for Bronchopulmonary Dysplasia (BPD)
Mar 26, 2021: Airway Therapeutics announces FDA acceptance of IND for AT-100 in preterm infants at risk for bronchopulmonary dysplasia (BPD)
Aug 23, 2019: Mediposts Pneumostem gets FDAs fast-track designation
May 15, 2019: Meridigen new Neonatal Stem Cell Drug received TFDA Approval for Clinical Trial
Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.
Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia
Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer
May 03, 2016: MEDIPOST receives US Patent for PNEUMOSTEM for Treating Lung Disease
Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial
Jul 29, 2014: Lung disease stem cell drug designated orphan drug in development stage
Feb 06, 2014: Stem cells to treat lung disease in preterm infants
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bronchopulmonary Dysplasia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bronchopulmonary Dysplasia - Pipeline by Advent Therapeutics Inc, 2022
Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics Inc, 2022
Bronchopulmonary Dysplasia - Pipeline by APIE Therapeutics Inc, 2022
Bronchopulmonary Dysplasia - Pipeline by Ayuvis Research Inc, 2022
Bronchopulmonary Dysplasia - Pipeline by Boehringer Ingelheim International GmbH, 2022
Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, 2022
Bronchopulmonary Dysplasia - Pipeline by Exo Biologics SA, 2022
Bronchopulmonary Dysplasia - Pipeline by Insmed Inc, 2022
Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, 2022
Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, 2022
Bronchopulmonary Dysplasia - Pipeline by Orphanix GmbH, 2022
Bronchopulmonary Dysplasia - Pipeline by Radikal Therapeutics Inc, 2022
Bronchopulmonary Dysplasia - Pipeline by Syntrix Pharmaceuticals, 2022
Bronchopulmonary Dysplasia - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Bronchopulmonary Dysplasia - Pipeline by The Cell Factory BVBA, 2022
Bronchopulmonary Dysplasia - Pipeline by Trimunocor Ltd, 2022
Bronchopulmonary Dysplasia - Pipeline by Velvio GmbH, 2022
Bronchopulmonary Dysplasia - Dormant Projects, 2022
Bronchopulmonary Dysplasia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Bronchopulmonary Dysplasia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $2000.00
  • $4000.00
  • $6000.00
  • ADD TO BASKET
  • BUY NOW